Many people have trouble deciding where to invest their money. There are so many options, but it can be difficult to decide which one of them is the best. However, the current market can seem like a bonanza for the risk-tolerant investor. Quality companies are available at a steep discount to historical highs because of…

During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms’ technologies are being widely-embraced by end users. Consequently, I believe that these names are destined to become hypergrowth stocks relatively soon. Also importantly, all three of…

It may seem a little crazy to talk about finding cheap penny stocks to buy at this time. The economy is cooling, and even blue-chip stocks are struggling to gain traction. However, there are several reasons for speculative investors to consider investing in penny stocks. First, investors will want to make note of an obvious…

After months of consolidation, Bionano Genomics (NASDAQ:BNGO) is breaking down. BNGO stock has plummeted 30% since announcing earnings in early November. While the earnings report was decent, some legitimate concerns and a lack of news continue to weigh on shares. Source: Shutterstock / PopTika I’ll admit the genome analysis company is compelling, but investors should wait…

Bionano Genomics (NASDAQ:BNGO) continues to take steps that will, in the long-term, tremendously boost its results and the share price. Consequently, I remain very bullish on BNGO stock. Source: Natali_ Mis/ShutterStock.com More specifically, the sales of Bionano’s Saphyr DNA mapping system are still accelerating, while a recent acquisition by the company should make the product…

Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a “hot stock,” a “meme stock” or whatever you want to call it. Since its big drop in late February and early March, the market has had mixed feelings about this life sciences company. Source: Natali_ Mis/ShutterStock.com Their view? On one hand, it…

Sometimes the market really likes life sciences company Bionano Genomics (NASDAQ:BNGO), but other times it’s indifferent. At the moment, BNGO stock is drifting along, waiting for a catalyst to push it higher. Source: Natali_ Mis/ShutterStock.com Just to give you a review, Bionano Genomics’ primary product is the Saphyr System. This is an optical genome mapping instrument…

Bionano Genomics (NASDAQ:BNGO) is having a good year. But it doesn’t have much to show for it. Since the company reported earnings on Aug. 3, BNGO stock is trading slightly lower. And since the beginning of the year, the stock is down 25%.   Source: Natali_ Mis/ShutterStock.com One reason for that may be that the company missed…

As the Covid-19 pandemic has developed and unfolded, the topic of variants has received considerable attention from the medical community as countries have watched new forms of the virus manifest. This trend has posed many negative effects regarding public health. However, for companies operating within the biotech sector, particularly those with a focus in infectious…

2021 has been an exciting year for BioNano Genomics (NASDAQ:BNGO) investors. However, when it comes to stocks, excitement can cut both ways. A spectacular run started last Christmas eve. It saw BNGO stock go from being worth 71 cents to closing at $15.57 on Feb. 16. That’s 2,093% growth. Pretty exciting — especially if you…

Bionano (NASDAQ:BNGO) stock has more going for it than many people may recognize. Among the most exciting is a financial incentive plan for its Saphyr genome mapping system. Source: Natali_ Mis/ShutterStock.com Bionano is taking several steps that should convince payors to reimburse healthcare facilities for using Bionano’s Saphyr device. I’m confident that such reimbursements will greatly…

There’s no denying that shares of life sciences company Bionano Genomics (NASDAQ:BNGO) aren’t as cheap as they were in 2020. Yet, due to a recent price pullback, BNGO stock is more attractive than it has been in a while. Source: Natali_ Mis/ShutterStock.com Like all biotechnology investments, there’s risk involved with Bionano Genomics. Yet, if you believe…

Based on my financial analysis, I would not touch Bionano Genomics (NASDAQ:BNGO) right now. I would run fast and far away from BNGO stock. But why? There are several reasons, and they all have to do with fundamentals. Source: Natali_ Mis/ShutterStock.com While the company has a positive catalyst here and there, its revenue and subsequent…

Bionano Genomics (NASDAQ:BNGO) stock, along with most other meme stocks, has been tumbling in recent weeks. But unlike most other meme names, Bionano has a highly disruptive product, and its shares are tremendously undervalued. BNGO stock is down 20.8% in the past month. Source: Connect world / Shutterstock.com As I’ve explained in other columns, Bionano’s…

With meme stocks starting to tumble and Wall Street becoming much more skeptical about Clover Health (NASDAQ:CLOV), the outlook of CLOV stock has deteriorated meaningfully in recent weeks. Source: Shutterstock Meanwhile, Clover’s claims to be a high-tech disruptor are questionable, and the company continues to face Securites and Exchange Commission and Department of Justice probes,…

Some people seem to believe that meme stocks cannot have good fundamentals and that names with strong fundamentals cannot be meme stocks. But I think that’s a misconception. In my mind, a meme stock is an equity that has rallied primarily because it’s been bought by retail investors in general and individuals who love talking…

Bionano Genomics (NASDAQ:BNGO) stock might appear interesting at first blush. After all, the company has developed an optical DNA mapping instrument called Saphyr. It is a high throughput system – which looks like a printer from the outside – that allows genome variations to be rapidly identified.  Source: Connect world / Shutterstock.com However, upon taking…

  • 1
  • 2